Haas M, Bahlinger V, Burger M, Bolenz C, Ma Y
Klinik für Urologie der Universität Regensburg, Caritas Krankenhaus St. Josef, Landshuter Str. 65, 93053, Regensburg, Deutschland.
Institut für Pathologie und Neuropathologie, Universitätsklinikum und Comprehensive Cancer Center Tübingen, Liebermeisterstr. 8, 71088, Tübingen, Deutschland.
Urologie. 2024 Oct;63(10):1011-1018. doi: 10.1007/s00120-024-02421-4. Epub 2024 Sep 2.
Upper tract urothelial carcinoma (UTUC) is a cancer that is often already in an advanced stage at the time of initial diagnosis. Although urothelial carcinoma of the upper and lower urinary tracts both originate from the urothelium and have similar genetic alterations, there are significant differences in their distribution. In localized high-risk UTUC, radical nephroureterectomy is the gold standard therapy. In metastatic UTUC, major changes are emerging in sequential therapy due to the investigation of new classes of drugs. In addition to platinum-based combination chemotherapy and immunotherapy, new substances such as antibody-drug conjugates (ADCs) and FGFR inhibitors are used.
上尿路尿路上皮癌（UTUC）是一种在初次诊断时通常已处于晚期的癌症。尽管上尿路和下尿路的尿路上皮癌均起源于尿路上皮且具有相似的基因改变，但其分布存在显著差异。在局限性高危UTUC中，根治性肾输尿管切除术是金标准治疗方法。在转移性UTUC中，由于对新型药物的研究，序贯治疗正在发生重大变化。除了铂类联合化疗和免疫治疗外，还使用了抗体药物偶联物（ADC）和FGFR抑制剂等新物质。
